BCR and cancer: Using the genomic DNA of 91 patients with CML collected at the time of diagnosis and at other time points, Roche-Lestienne et al. examined four cancer genes, TET2, IDH1, IDH2, and ASXL1, which had been commonly reported in BCR::ABL1-negative hematological cancers.